EPGL
SLS icon

Evelyn Partners Group Ltd’s SELLAS Life Sciences SLS Stock Holding History

Evelyn Partners Group Ltd’s Portfolio SLS Stock Details SLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.64K Buy
+450
New +$3.11K ﹤0.01% 498

Other funds holding SLS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DI
DAGCO Inc Westlake, Ohio $541M AUM 29.31% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
OCG
Opus Capital Group Cincinnati, Ohio $1.03B AUM 20.67% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Evelyn Partners Group Ltd's SLS Position: Q2 2026 in Review

Evelyn Partners Group Ltd opened a new position in SELLAS Life Sciences (SLS) in Q2 2026: 450 shares worth $6.64K. The stake represents ﹤0.01% of the portfolio and ranks #498 among its holdings.

84 funds tracked by Wall St. Rank hold SLS as of Q2 2026.

  • Evelyn Partners Group Ltd held 450 shares of SELLAS Life Sciences worth $6.64K as of Q2 2026.
  • SELLAS Life Sciences was a new Evelyn Partners Group Ltd position in Q2 2026.
  • SELLAS Life Sciences made up ﹤0.01% of Evelyn Partners Group Ltd's portfolio in Q2 2026, its #498 holding.
  • 84 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q2 2026.

Based on Evelyn Partners Group Ltd's 13F filing for Q2 2026, filed 7 Aug 2026.